Treatment for Alcohol Use Disorder
Understanding the Spectrum of Alcohol Use — and When to Seek Treatment
Alcohol Use Disorder is not an "all or nothing" diagnosis; it exists on a spectrum from mild to severe. Many of our patients are high-functioning professionals who may not fit the traditional stereotype of addiction but recognize that alcohol has begun to interfere with their health, sleep, or executive performance.
Common indicators that it may be time to seek specialized medical support include:
Increased Tolerance: Needing significantly more alcohol to achieve the same effect.
The "Internal Monologue": Spending significant mental energy planning when to drink or trying to "control" intake.
Biological Feedback: Experiencing "3 AM insomnia," increased heart rate, or morning anxiety (the "rebound effect").
Failed Transitions: Repeatedly intending to take a "break" or "dry month" only to find yourself returning to old patterns.
Expertise in Addiction Medicine
With over 24 years of clinical experience, Falk W. Lohoff, MD, has dedicated his career to diagnosing and treating the full spectrum of Alcohol Use Disorder (AUD). As a double board-certified psychiatrist with specialized training from the University of Pennsylvania, Dr. Lohoff combines decades of frontline patient care with a deep background in clinical research.
This extensive experience allows him to look past the surface-level symptoms of addiction to identify the complex neurobiological and genetic drivers unique to each individual. Having helped thousands of patients navigate the challenges of recovery, Dr. Lohoff provides a level of expertise that ensures your treatment is not based on guesswork, but on a quarter-century of proven medical insight and state-of-the-art psychopharmacology.
Medication-Assisted Treatment (MAT) for Alcohol Use Disorder
Recovery from Alcohol Use Disorder (AUD) is rarely a linear journey because the condition itself is a complex intersection of biology, environment, and personal history. We believe in treating the whole person, not just a set of symptoms. By bridging the gap between state-of-the-art neuro-pharmacology and individual psychotherapy, we provide a stabilizing foundation that honors your unique circumstances. Our goal is to quiet the physiological noise of addiction, empowering you to engage fully in the deeper work of emotional and behavioral healing.
FDA-Approved Medications for AUD
We offer the three primary medications approved by the FDA for the treatment of AUD. The "best" choice depends on your specific goals—whether that is total abstinence or a significant reduction in heavy drinking.
Naltrexone (Oral & Injectable): * How it works: It blocks the opioid receptors in the brain that produce the "buzz" or euphoria from alcohol. By removing the reward, it helps break the cycle of craving. We can also discuss targeted pharmacological extinction strategies, such as the Sinclair Method, for patients whose goal is controlled reduction rather than immediate abstinence.
Vivitrol®: We also offer the once-monthly injectable version (Vivitrol) for patients who prefer not to take a daily pill, ensuring consistent protection against cravings.
Acamprosate (Campral):
How it works: This is ideal for those who have already stopped drinking. It helps stabilize brain chemistry that has been "hyperexcited" by long-term alcohol use, reducing the restlessness, anxiety, and insomnia that often lead to early relapse.
Disulfiram (Antabuse):
How it works: A traditional "deterrent" medication. It interferes with how the body breaks down alcohol, causing an immediate unpleasant reaction if alcohol is consumed. This is often used for patients who need an extra layer of accountability.
Innovative & Off-Label Approaches for AUD
In addition to standard treatments, our practice stays at the forefront of psychiatric research. We may consider "off-label" evidence-based options for patients who haven't found success with traditional medications:
Gabapentin & Topiramate: These medications can be highly effective in reducing heavy drinking days and managing the "protracted withdrawal" symptoms like anxiety and irritability.
GLP-1 and GLP-1/GIP Receptor Agonists (The "Semaglutide" Connection): Emerging research in 2026 suggests that medications originally used for metabolic health may also reduce the brain's reward-seeking behavior for alcohol.
Precision Recovery Protocols for AUD
We utilize a medical model for recovery that integrates metabolic health, genomic medicine, advanced psychopharmacology and psychotherapy:
Neuro-Metabolic Repair: Chronic substance use accelerates biological aging and disrupts cellular energy. We use biomarker testing to identify and repair the metabolic damage caused by long-term exposure.
Pharmacogenetic Guidance: We analyze your genetic profile to determine the most effective medications for craving management and relapse prevention, reducing the "trial and error" of traditional prescribing.
GLP-1 & Metabolic Hormone Insight: Based on Dr. Lohoff's extensive published research on the neurobiology of addiction and GLP-1 pathways, we explore how metabolic signaling (such as GLP-1 pathways) can be leveraged to quiet the brain’s "hunger" for substances.
Co-Occurring Disorder Mastery: We simultaneously treat the underlying depression, anxiety, or ADHD that often fuels the cycle of use, ensuring that the "root cause" is addressed alongside the addiction.
The Experience: What to Expect
Our approach to recovery is discreet, data-driven, and focused on long-term neurological restoration. Our addiction recovery and AUD treatments are available to residents throughout the D.C. Metro area, including Chevy Chase, Bethesda, Potomac, and Northern Virginia. We offer a discreet, professional environment for high-performing individuals seeking specialized psychiatric care.
Neuro-Diagnostic Assessment: A comprehensive 60-90-minute evaluation exploring the history of use, co-occurring conditions (like Depression, ADHD or Anxiety), and the specific triggers of your reward system.
Biological Restoration Mapping: We use advanced labs and genomic testing to identify the physiological "damage" caused by dependency and the genetic keys to your recovery.
The Freedom Blueprint: You receive a custom plan integrating precision medication, metabolic repair, and therapeutic strategies designed to restore your brain’s natural dopamine balance.
Sustained Resilience: Recovery is a dynamic process. We provide ongoing calibration of your treatment to ensure your brain remains resilient against stress, preventing relapse before it starts.
Clinical Research & Selected Publications by Dr. Lohoff
Treatment approaches for alcohol use disorder with metabolic dysfunction.Pharmacology & Therapeutics, 2026 >The Insight: This research highlights the critical link between the body's metabolic state and the brain's ability to recover. We treat the whole system—liver health, insulin sensitivity, and brain function—to ensure a robust recovery.
Genetically modeled GLP1R and GIPR agonism reduce binge drinking and alcohol-associated phenotypes: a multi-ancestry drug-target Mendelian randomization study.Molecular Psychiatry, 2025 > The Insight: This study explores how metabolic hormones can be targeted to reduce addictive behaviors. It informs our use of cutting-edge treatments that target the molecular hunger of the reward system.
A multi-omics Mendelian randomization study identifies new therapeutic targets for alcohol use disorder and problem drinking. Nature Human Behavior, 2025 > The Insight: By integrating "multi-omics" data—looking across genes, proteins, and metabolites—this research uses advanced statistical modeling to identify the actual causal drivers of addiction. This allows us to move beyond standard medications and target the specific biological pathways that trigger problem drinking, opening the door for truly personalized, precision addiction medicine.
Targeting Unmet Clinical Needs in the Treatment of Alcohol Use Disorder. Frontiers in Psychiatry, 2022 > The Insight: This work identifies the critical gaps in current addiction treatment—specifically why standard therapies often fail for certain patients. In our practice, we use these insights to address "unmet needs" by integrating metabolic and genomic data, ensuring that patients who have struggled with traditional recovery programs finally have a scientifically tailored path forward.